CAMBRIDGE, Mass., Jan. 2 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that Idenix management will present a corporate overview, including an update of the company's HCV and HIV discovery and development programs, at the upcoming JP Morgan 26th Annual Healthcare Conference on Tuesday, January 8, 2008 at 2:30 p.m. PT at the Westin St. Francis Hotel in San Francisco.
The live and archived webcasts of the presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://ir.idenix.com/phoenix.zhtml?c=131556&p=irol- EventDetails&EventId=1652955 (Due to URL length, please copy and paste into browser). Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.
About Idenix Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com/.
Idenix Pharmaceuticals' Contacts:
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838
DATASOURCE: Idenix Pharmaceuticals, Inc.
CONTACT: Media, Teri Dahlman, +1-617-995-9905, or Investors, Amy Sullivan, +1-617-995-9838, both of Idenix Pharmaceuticals, Inc.
Web site: http://www.idenix.com/
|